CRSP Relative Valuation
CRSP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CRSP is overvalued; if below, it's undervalued.
Historical Valuation
CRISPR Therapeutics AG (CRSP) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -13.25. The fair price of CRISPR Therapeutics AG (CRSP) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 55.99 USD , CRISPR Therapeutics AG is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：55.99
Fair
Undervalued
-12.99
PE
1Y
3Y
5Y
Trailing
Forward
-8.30
EV/EBITDA
CRISPR Therapeutics AG. (CRSP) has a current EV/EBITDA of -8.30. The 5-year average EV/EBITDA is -8.00. The thresholds are as follows: Strongly Undervalued below -41.60, Undervalued between -41.60 and -24.80, Fairly Valued between 8.80 and -24.80, Overvalued between 8.80 and 25.59, and Strongly Overvalued above 25.59. The current Forward EV/EBITDA of -8.30 falls within the Historic Trend Line -Fairly Valued range.
-7.30
EV/EBIT
CRISPR Therapeutics AG. (CRSP) has a current EV/EBIT of -7.30. The 5-year average EV/EBIT is -42.43. The thresholds are as follows: Strongly Undervalued below -374.85, Undervalued between -374.85 and -208.64, Fairly Valued between 123.78 and -208.64, Overvalued between 123.78 and 289.99, and Strongly Overvalued above 289.99. The current Forward EV/EBIT of -7.30 falls within the Historic Trend Line -Fairly Valued range.
184.06
PS
CRISPR Therapeutics AG. (CRSP) has a current PS of 184.06. The 5-year average PS is 256.07. The thresholds are as follows: Strongly Undervalued below -531.84, Undervalued between -531.84 and -137.89, Fairly Valued between 650.02 and -137.89, Overvalued between 650.02 and 1043.98, and Strongly Overvalued above 1043.98. The current Forward PS of 184.06 falls within the Historic Trend Line -Fairly Valued range.
-20.53
P/OCF
CRISPR Therapeutics AG. (CRSP) has a current P/OCF of -20.53. The 5-year average P/OCF is 53.73. The thresholds are as follows: Strongly Undervalued below -491.47, Undervalued between -491.47 and -218.87, Fairly Valued between 326.34 and -218.87, Overvalued between 326.34 and 598.94, and Strongly Overvalued above 598.94. The current Forward P/OCF of -20.53 falls within the Historic Trend Line -Fairly Valued range.
-20.50
P/FCF
CRISPR Therapeutics AG. (CRSP) has a current P/FCF of -20.50. The 5-year average P/FCF is 213.17. The thresholds are as follows: Strongly Undervalued below -1639.67, Undervalued between -1639.67 and -713.25, Fairly Valued between 1139.59 and -713.25, Overvalued between 1139.59 and 2066.01, and Strongly Overvalued above 2066.01. The current Forward P/FCF of -20.50 falls within the Historic Trend Line -Fairly Valued range.
CRISPR Therapeutics AG (CRSP) has a current Price-to-Book (P/B) ratio of 2.74. Compared to its 3-year average P/B ratio of 2.35 , the current P/B ratio is approximately 16.91% higher. Relative to its 5-year average P/B ratio of 2.85, the current P/B ratio is about -3.62% higher. CRISPR Therapeutics AG (CRSP) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -6.60%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -3.60% , the current FCF yield is about -100.00% lower.
2.85
P/B
Median3y
2.35
Median5y
2.85
-5.68
FCF Yield
Median3y
-6.60
Median5y
-3.60
Competitors Valuation Multiple
The average P/S ratio for CRSP's competitors is 1.79, providing a benchmark for relative valuation. CRISPR Therapeutics AG Corp (CRSP) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 47.67%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of CRSP increased by 47.82% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 602.00K to 889.00K.
The secondary factor is the P/E Change, contributed 16.28%to the performance.
Overall, the performance of CRSP in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is CRISPR Therapeutics AG (CRSP) currently overvalued or undervalued?
What is CRISPR Therapeutics AG (CRSP) fair value?
How does CRSP's valuation metrics compare to the industry average?
What is the current P/B ratio for CRISPR Therapeutics AG (CRSP) as of Dec 05 2025?
What is the current FCF Yield for CRISPR Therapeutics AG (CRSP) as of Dec 05 2025?
What is the current Forward P/E ratio for CRISPR Therapeutics AG (CRSP) as of Dec 05 2025?